Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

BURNABY, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 13th Annual Wedbush PacGrow (Virtual) Healthcare Conference.

Fireside Chat Details:  
   
Date:   Wednesday, August 10, 2022
   
Time:   2:55-3:25 pm ET
   
Presenters: Ian Mortimer, President and CEO
  Sherry Aulin, CFO

A webcast of the fireside chat will be available on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com

Staff

Recent Posts

FendX Announces Webinar on April 11, 2024 to Showcase Recent Achievements and Provides Corporate Update

Oakville, Ontario--(Newsfile Corp. - April 3, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

57 mins ago

Shifa Health Marks 21 Years of Transformative Mental Health Care

A Celebration of Innovation, Compassion, and Community EngagementEVERETT, WA / ACCESSWIRE / April 3, 2024…

2 hours ago

Bulletin from the Extraordinary General Meeting of PMD Device Solutions AB held on 3 April 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) PMD Device…

2 hours ago

AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB…

2 hours ago

Berlin Cures Expands Research Capabilities and Scientific Expertise with New Advisory Board

BERLIN, GERMANY / ACCESSWIRE / April 3, 2024 / Berlin Cures, a biotechnology company in…

5 hours ago

Mars Veterinary Health pilots industry-leading anaesthetic gas capture technology to reduce carbon emissions

World's leading provider of veterinary care will be first to introduce innovative in-clinic solution to…

8 hours ago